POET Plunges on $400M Stock Sale, Dilution Fears Intensity

What happened

POET Technologies shares fell sharply this week after the company announced a $400 million stock sale, a move that amplifies the already significant dilution risk flagged in our analysis. The company, which generated just $1.1 million in revenue in FY2025 and reported a $63 million net loss, has been funding operations primarily through equity issuances. This latest offering, which includes 19 million shares and warrants for another 19 million, adds to the nearly $300 million raised in FY2025 and the $150 million direct offering earlier in 2026. Given that customers can cancel purchase orders without penalty—as demonstrated by the Marvell/Celestial cancellation—and that the flagship Lumilens order remains gated by qualification milestones, the capital raise underscores the gap between the company's cash burn and its commercial progress. The market's reaction reflects a growing realization that shareholder value is being eroded by repeated dilution without commensurate revenue inflection.

Implication

The equity raise reinforces our bearish thesis: POET burns cash at a rate that requires constant capital infusions, and the revenue base is too small to justify the current market cap. Until the company demonstrates conversion of milestone-gated orders into repeatable revenue and provides manufacturing KPIs, the stock remains a show-me story with high downside risk. The base case value of $14 assumes successful ramp, but the bear case of $9 is more plausible given the dilution overhang and cancellable PO structure.

Thesis delta

The $400M equity raise shifts the thesis from 'funding for growth' to 'dilution without execution.' It increases the share count by 13% immediately (with additional warrants) and signals that management is prioritizing liquidity over shareholder value. This makes the bear case more probable, as the company's path to profitability becomes even more reliant on large, uncertain order conversions.